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http://breast-cancer-research.com/content/16/3/R50RESEARCH ARTICLE Open AccessRelationship between HER2 expression and
efficacy with first-line trastuzumab emtansine
compared with trastuzumab plus docetaxel in
TDM4450g: a randomized phase II study of patients
with previously untreated HER2-positive metastatic
breast cancer
Edith A Perez1*, Sara A Hurvitz2, Lukas C Amler3, Kirsten E Mundt3, Vivian Ng3, Ellie Guardino3 and Luca Gianni4Abstract
Introduction: The purpose of this study was to retrospectively explore the relationship between human epidermal
growth factor receptor 2 (HER2) messenger RNA (mRNA) expression and efficacy in patients receiving trastuzumab
plus docetaxel (HT) or trastuzumab emtansine (T-DM1).
Methods: Patients with HER2-positive, locally advanced or metastatic breast cancer (MBC) were randomly assigned
to HT (n = 70) or T-DM1 (n = 67). HER2 status was assessed locally using immunohistochemistry or fluorescence in
situ hybridization and confirmed retrospectively by central testing. HER2 mRNA expression was assessed using
quantitative reverse transcriptase polymerase chain reaction.
Results: HER2 mRNA levels were obtained for 116/137 patients (HT = 61; T-DM1 = 55). Median pretreatment HER2
mRNA was 8.9. The risk of disease progression in the overall population was lower with T-DM1 than with HT (hazard
ratio (HR) = 0.59; 95% confidence interval (CI) 0.36 to 0.97). This effect was more pronounced in patients with HER2
mRNA ≥median (HR = 0.39; 95% CI 0.18 to 0.85) versus < median (HR = 0.85; 95% CI 0.44 to 1.67). In the T-DM1 arm,
median progression-free survival (PFS) was not reached in patients with HER2 mRNA ≥median and was 10.6 months
in patients with HER2 mRNA < median. In the HT arm, PFS was 8.8 versus 9.8 months in patients with HER2
mRNA ≥ median versus < median, respectively. The effect of HER2 mRNA expression on objective response rates
was less pronounced.
Conclusions: This exploratory analysis suggests that while overall, patients with HER2-positive MBC show improved
PFS with T-DM1 relative to HT, the effect is enhanced in patients with tumor HER2 mRNA ≥median.
Trial registration: ClinicalTrials.gov NCT00679341* Correspondence: perez.edith@mayo.com
1Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA
Full list of author information is available at the end of the article
© 2014 Perez et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
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Adding human epidermal growth factor receptor 2 (HER2)-
targeted agents such as trastuzumab, trastuzumab and per-
tuzumab, or lapatinib to chemotherapy can improve clinical
outcomes for patients with HER2-positive metastatic breast
cancer (MBC) [1-5]. Despite receiving treatment with these
agents, however, patients will eventually develop disease
progression, and novel HER2-directed therapies are still
needed.
Trastuzumab emtansine (T-DM1), which was recently
approved as a single agent for the treatment of HER2-
positive MBC, is an antibody-drug conjugate comprising
trastuzumab stably linked to DM1, which is a potent
cytotoxic agent derived from the antimicrotubule agent
maytansine [6]. The trastuzumab component of T-DM1
targets the agent to HER2-expressing tumor cells, within
which it is internalized and lysine-Nε-4 -MCC-DM1 is
released intracellularly, resulting in microtubule instability
and apoptosis [6,7]. Like trastuzumab, T-DM1 also in-
duces antibody-dependent cellular cytotoxicity, inhibits
HER2 pathway proliferative signaling, and inhibits HER2
shedding [8]. In the pivotal phase III EMILIA trial
(NCT00829166), patients with pretreated (trastuzumab
and a taxane), HER2-positive locally advanced or MBC
were randomly assigned to T-DM1 or capecitabine
plus lapatinib [9]. Patients who received T-DM1 had
significant improvements in both progression-free sur-
vival (PFS) and overall survival (OS) compared with those
in the comparator arm [9]. Significant improvements in
PFS were also reported in the randomized phase II
TDM4450g (BO21976; NCT00679341) study, in which
patients with previously untreated MBC received ei-
ther trastuzumab plus docetaxel (HT) or T-DM1 [10].
Results from exploratory analyses of single-arm, phase
II studies of T-DM1 in patients with MBC (TDM4258g
and TDM4374g) suggest that greater expression of HER2
messenger RNA (mRNA), which was assessed using quan-
titative reverse transcriptase polymerase chain reaction
(qRT-PCR), may correlate with greater objective response
rates (ORRs) and longer PFS [11,12]. Here we report the
results from an exploratory analysis of data from the
TDM4450g (BO21976) study, to examine whether HER2
expression (assessed by qRT-PCR) correlates with clin-
ical benefit reported in patients receiving treatment
with T-DM1 in this study.
Materials and methods
Patients
Eligible patients were ≥18 years of age with unresectable,
HER2-positive, locally advanced MBC and/or MBC that
had not been treated with prior chemotherapy (prior
hormonal therapy was allowed). Patients had measurable
disease, as assessed by the response evaluation criteria in
solid tumors [13], an Eastern Cooperative Oncology Group(ECOG) performance status (PS) of 0 or 1, and adequate
organ function. Detailed information on the methodology
employed in this study has been published elsewhere [10].Study design
In this phase II, multicenter, open-label study, patients
were randomly assigned (1:1 ratio) to T-DM1 (3.6 mg/kg
intravenous (IV) every 3 weeks), or trastuzumab (8 mg/
kg IV on cycle 1, day 1, followed by 6 mg/kg IV every
3 weeks) plus docetaxel (75 mg/m2 or 100 mg/m2 IV).
Treatments were given until disease progression, un-
acceptable toxicity, or study closure. The primary effi-
cacy end point was investigator-assessed PFS. A number
of exploratory end points were also investigated, includ-
ing the relationship between the levels of HER2 mRNA
expression and efficacy outcomes.
All participating study sites had institutional review
board (IRB) approval of the protocol (see list of IRBs in
Additional file 1). The study was conducted in accord-
ance with the Declaration of Helsinki, the US Food and
Drug Administration Good Clinical Practices, and local
laws. All patients provided written informed consent.HER2 quantification
Tumor HER2 status was established by local laboratory
testing, using either immunohistochemistry (IHC; posi-
tive result: 3+ staining intensity in >10% of cells) or
fluorescence in situ hybridization (FISH; positive result:
HER2/chromosome 17 centromere ratio ≥2.0). Archival
tumor tissue (paraffin block and/or slides) was also sent
for central confirmation of HER2 status using FISH and
IHC at Targos Molecular Pathology GmbH (Kassel,
Germany), but central HER2 testing was not required
for initiation of treatment. HER2 protein expression
was assessed using the HercepTest™ kit (Dako North
America, Inc., Carpinteria, CA, USA). HER2 gene amplifi-
cation was assessed using the standard PathVysion HER2
FISH kit (Abbott Molecular, Abbott Park, IL, USA). Both
methods were carried out in accordance with the manu-
facturers’ instructions and with the instructions in the
trastuzumab prescribing information [14].
Samples that were sent for central HER2 testing were
also used for analysis of HER2 mRNA expression by
qRT-PCR at the same central laboratory. To allow for
analysis of mRNA as a continuous variable, mRNA ex-
pression was measured in samples from all randomly
assigned patients regardless of the HER2 status estab-
lished by central review. RNA was extracted and analyzed
using the LightCycler® (Roche Applied Sciences, Mannheim,
Germany) in accordance with the manufacturer’s instruc-
tions. The HER2 mRNA values obtained were relative to the
housekeeping gene Glucose-6-phosphate dehydrogenase.
Table 1 Selected patient demographic and baseline
characteristics by treatment arm
Characteristic HT (n = 70) T-DM1 (n= 67)
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Methods used for tumor assessments and clinical out-
comes have been published previously [10].Median age, years (range) 52.0 (33 to 75) 55.0 (27 to 82)
World region, %
North America 28.6 31.3
Central and South America 28.6 23.9
Europe 42.9 44.8
Race, %
White 82.9 77.6
American Indian or Alaskan native 10.0 7.5
Black 4.3 4.5
Other or not available 2.9 10.4
ECOG PS, %
0 63.8a 65.7
1 36.2a 34.3
HER2 status by central laboratory, %b
HER2-positive 85.9 85.7
Normal 14.1 14.3
ER/PR status, %
ER-positive and/or PR-positive 54.3 49.3
ER-negative and PR-negative 41.4 47.8
ER and PR unknown 4.3 3.0
Stage at initial diagnosis, %
Stage I to III 68.1a 58.2
Stage IV 29.0a 34.3
Unknown 2.9a 7.5
Number of distinct sites of involvement
1 to 2 49.3a 35.8Statistical analysis
This study had a hypothesis-generating statistical design.
The study sponsor collected and analyzed the data, au-
thors were involved in the study design, and all authors
had access to the primary data. Demographic variables
and baseline characteristics were summarized by treat-
ment arm and by treatment arm and HER2 mRNA expres-
sion. Pretreatment HER2 mRNA values were summarized
by treatment arm. The hazard ratio (HR) of PFS comparing
T-DM1 with HT and its 95% CI was estimated from a Cox
proportional hazards model by HER2 mRNA subgroups.
Kaplan-Meier estimates of PFS and median PFS were pre-
sented by HER2 mRNA subgroups. An estimate of the
ORR was calculated for each treatment arm by HER2
mRNA subgroups.
Multivariate Cox regression analysis was performed to
estimate treatment effect adjusting for multiple prognos-
tic baseline covariates. The variables tested in the model
included age, race, world region, ECOG PS, progester-
one receptor (PR) and estrogen receptor (ER) status,
central HER2 status, number of disease sites, disease
measurability, disease-free interval, disease stage at ini-
tial diagnosis, menopausal status, prior anthracycline, prior
taxane, prior trastuzumab, prior taxane and trastuzumab,
prior taxane or trastuzumab, lung or liver involvement,
prior hormonal therapy, prior radiotherapy, and HER2
mRNA (below the median versus equal to or higher than
the median for the overall population). A stepwise proced-
ure was used to determine the final model.>2 50.7a 64.2
Lung or liver involvement. %
Yes 67.1 71.6
No 31.4 26.9
Unknown 1.4 1.5
Disease-free interval, %
≤24 months 64.3 59.7Results
The database lock for the primary efficacy analysis took
place on 15 November 2010 after 75 investigator-assessed
PFS events had taken place in the two treatment arms
combined, as pre-specified in the statistical analysis plan
of the study.>24 months 35.7 40.3
Prior treatment. %
Trastuzumab 27.1 17.9
Taxane 40.0 32.8
Anthracycline 48.6 44.8
Total number of prior chemotherapy
agents, median (range)
3 (1 to 4) 3 (1 to 6)
Reproduced with permission from Hurvitz et al. [10]. aData were available for 69
patients in the HT arm. bCentral testing for HER2 status was performed for 64
patients in the HT arm and 63 patients in the T-DM1 arm. ECOG PS, Eastern
Cooperative Oncology Group performance status; ER, estrogen receptor;
HER2, human epidermal growth factor receptor 2; HT, trastuzumab plus docetaxel;
PR, progesterone receptor; T-DM1, trastuzumab emtansine.Patient characteristics
In total, 137 patients were randomly assigned to treat-
ment with either HT (n = 70) or T-DM1 (n = 67) (see
Additional file 2 for CONSORT diagram). Baseline charac-
teristics were similar between the treatment arms (Table 1),
with the exception that more patients in the HT arm were
first diagnosed at an earlier disease stage (stage I to III at
diagnosis was 68.1% with HT versus 58.2% with T-DM1).
Consistent with this, more patients in the HT arm had re-
ceived prior (neo) adjuvant therapy with trastuzumab
(27.1% versus 17.9%) or a taxane (40.0% versus 32.8%).
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Details of treatment duration and discontinuation have
been published previously [10].
HER2 quantification
Of the 137 randomized patients, 127 (63 in the T-DM1
arm; 64 in the HT arm) had tumor samples analyzed
centrally for confirmatory HER2 testing. Testing was
performed on the primary tumor in 89 patients, on a
metastatic lesion in 12 patients, and the status of the
tumor (that is, primary or metastatic) was not reported
or was unknown in 36 patients. At the time of this ana-
lysis 85.7% of patients in the T-DM1 arm and 85.9% of
patients in the HT arm had confirmed centrally tested
HER2-positive primary tumors. Valid results for the as-
sessment of pretreatment HER2 mRNA were obtained
for 116 patients, with 55 in the T-DM1 arm and 61 in
the HT arm. Results for six samples were below the limit
of quantification, and there was not enough tissue avail-
able to run the analyses for five patients. The medianTable 2 Selected patient demographic and baseline character
Characteristic HER2 mRNA <medi
HT T-DM1
(n = 32) (n = 26)
Median age, years (range) 52.5 54.5
(36 to 72) (32 to 74
World region, %
US 34.4 38.5
Non-US 65.6 61.5
Race, %a
White 81.3 80.8
American Indian or Alaskan native 9.4 7.7
Black 6.3 0.0
Other or not available 3.1 11.5
ECOG PS, %
0 62.5 80.8
1 37.5 19.2
HER2 status by central laboratory, %
HER2-positive 71.9 73.1
Normal 28.1 26.9
ER/PR status, %a
ER-positive and/or PR-positive 65.6 57.7
ER-negative and PR-negative 28.1 42.3
ER and PR unknown 6.3 0
Number of distinct sites involveda
1 to 2 43.8 30.8
>2 56.3 69.2
aPercentages may not add to 100% due to rounding. ECOG PS, Eastern Cooperative
epidermal growth factor receptor 2; HT, trastuzumab plus docetaxel; mRNA, messen(range) pretreatment levels of HER2 mRNA in the over-
all patient population were 8.9 (0.4 to 105.0; units used
were the concentration ratio). Median (range) pretreat-
ment levels of HER2 mRNA were 10.3 (0.4 to 103.0) in
the T-DM1 arm and 8.7 (0.5 to 105.0) in the HT arm.
Baseline patient and tumor characteristics were gener-
ally similar between patients with HER2 mRNA expres-
sion equal to or greater than the median (that is, the
median of the overall study population) and below the
median (that is, the median of the overall study popula-
tion), regardless of the treatment arm (Table 2) with
some exceptions. A greater proportion of patients in the
subgroup with HER2 mRNA expression equal to or
greater than the median had centrally confirmed HER2
status (100% versus 72.4%). In addition, a greater pro-
portion of patients with median tumor expression of
HER2 mRNA equal to or greater than the median ver-
sus below the median were from outside of the US
(74.1% versus 63.8%), had ER-negative and/or PR-
negative tumors (50.0% versus 34.5%), and equal to oristics by HER2 mRNA expression and treatment arm
an (n = 58) HER2 mRNA ≥median (n = 58)
Total HT T-DM1 Total
(n = 58) (n = 29) (n = 29) (n = 58)
53.5 51.0 54.0 53.0
) 32 to 74 (33 to 75) (27 to 82) (27 to 82)
36.2 24.1 27.6 25.9
63.8 75.9 72.4 74.1
81.0 86.2 72.4 79.3
8.6 6.9 6.9 6.9
3.4 3.4 6.9 5.2
6.9 3.4 13.8 8.6
70.7 57.1 69.0 63.2
29.3 42.9 31.0 36.8
72.4 100.0 100.0 100.0
27.6 0.0 0.0 0.0
62.1 48.3 44.8 46.6
34.5 48.3 51.7 50.0
3.4 3.4 3.4 3.4
37.9 50.0 44.8 47.4
62.1 50.0 55.2 52.6
Oncology Group performance status; ER, estrogen receptor; HER2, human
ger RNA; PR, progesterone receptor; T-DM1, trastuzumab emtansine.
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37.9%).
Among patients with HER2 mRNA expression equal
to or greater than the median, a greater proportion of
patients in the T-DM1 arm relative to the HT arm had
ECOG PS of 0 (69.0% versus 57.1%) and more patients
in the HT arm were white (86.2% versus 72.4%) (Table 2).
Among patients with HER2 mRNA expression below the
median, a greater proportion of patients in the T-DM1
arm relative to the HT arm had ECOG PS 0 (80.8% ver-
sus 62.5%), ER-negative/PR-negative tumors (42.3% versus
28.1%), and more than two sites of disease involvement
(69.2% versus 56.3%).
Clinical outcomes by HER2 expression
The PFS benefit with T-DM1 in patients with centrally
confirmed HER2-positive tumors (median PFS in the
T-DM1 arm versus the HT arm 14.2 months versus
9.8 months; HR for PFS 0.57, 95% CI 0.32, 1.04) was
similar to that seen in the overall study population
(median PFS in the T-DM1 arm versus the HT arm
14.2 months versus 9.2 months; HR for PFS 0.59, 95%
CI 0.36, 0.97).
Efficacy outcomes (PFS and ORR) by HER2 mRNA ex-
pression level are summarized by treatment arm in
Table 3. Kaplan-Meier estimates of PFS by HER2 mRNA
expression for both treatment arms are presented inTable 3 Efficacy outcomes by tumor HER2 expression
below the median and equal to or greater than the
median
Median PFS,
months
HER2 expressiona HT T-DM1 HR relative to HT (95% CI)
All patients (n = 70) (n = 67) 0.59 (0.36, 0.97)
9.2 14.2
< Median (n = 32) (n = 26) 0.85 (0.44, 1.67)
9.8 10.6
≥ Median (n = 29) (n = 29) 0.39 (0.18, 0.85)
8.8 Not reached
ORR,%
HER2 expressiona HT T-DM1 Odds ratio relative
to HT (95% CI)
All patients (n = 69) (n = 67) 1.26 (0.63, 2.55)
58.0 64.2
< Median (n = 31) (n = 26) 0.84 (0.30, 2.41)
58.1 53.8
≥ Median (n = 29) (n = 29) 1.58 (0.50, 4.98)
65.5 72.4
aHER2 mRNA data were available for 61 of 70 patients in the HT arm and for 55
of 67 patients in the T-DM1 arm. HER2, human epidermal growth factor
receptor 2; HT, trastuzumab plus docetaxel; ORR, objective response rate;
PFS, progression-free survival; T-DM1, trastuzumab emtansine.Figure 1A (expression below the median) and Figure 1B
(expression equal to or greater than the median). The
HRs/odds ratios and 95% CIs for PFS and ORR were cal-
culated by HER2 mRNA subgroup (that is, equal to or
greater than the median versus below the median, and
by quartile) and are presented in Forrest plots in Figure 2
and Figure 3, respectively.
The risk of disease progression for all randomized pa-
tients was lower with T-DM1 than with HT (HR 0.59,
95% CI 0.36, 0.97) (Table 3). This effect was more pro-
nounced in patients with tumor HER2 mRNA equal to
or greater than the median (HR 0.39, 95% CI 0.18, 0.85)
versus below the median (HR 0.85, 95% CI 0.44, 1.67).
The magnitude of the difference in median PFS between
the two treatment arms was greater in patients with tu-
mors exhibiting HER2 expression equal to or greater
than the median. Median PFS in patients with equal to or
greater than the median HER2 expression was 8.8 months
in the HT arm and was not reached in the T-DM1 arm
(HR 0.39, 95% CI 0.18, 0.85). For patients with tumor
HER2 expression below the median, median PFS was
9.8 months versus 10.6 months in the HT and T-DM1
arms, respectively (HR 0.85, 95% CI 0.44, 1.67).
In the T-DM1 treatment arm, median PFS was numer-
ically longer in patients with HER2 expression equal to
or greater than the median compared with those with
HER2 expression below the median (not reached versus
10.6 months, respectively). In the HT arm, duration of
PFS was similar in patients with HER2 expression equal
to or greater than the median and below the median (8.8
versus 9.8 months, respectively).
In the overall patient population, the ORR in the T-DM1
arm was numerically greater than that in the HT arm
(64.2% versus 58.0%; odds ratio 1.26, 95% CI 0.63, 2.55).
For patients with tumor HER2 expression equal to or
greater than the median, the ORR in the T-DM1 arm ver-
sus the HT arm was 72.4% versus 65.5% (odds ratio 1.58,
95% CI 0.50, 4.98). For patients with tumor HER2 expres-
sion below the median, the ORR was lower in the T-DM1
arm compared with the HT arm (53.8% versus 58.1%; odds
ratio 0.84, 95% CI 0.30, 2.41).Results from the multivariate
analyses indicated that after adjusting for baseline factors,
including HER2 mRNA expression, there is a trend in
PFS benefit for treatment with T-DM1 (HR 0.72, 95%
CI 0.41, 1.27).
Discussion
The TDM4450g (BO21976) study showed that treatment
with single-agent T-DM1 as first-line treatment for
MBC significantly improves PFS with a more favorable
safety profile compared with combined HT treatment
[10]. The PFS benefit was similar between the overall
study population and in patients with centrally con-
firmed PFS in the primary analysis [10] as well as in
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Figure 1 Kaplan-Meier estimates of progression-free survival (PFS) by HER2 mRNA expression below the median and equal to or
greater than median. (A) Kaplan-Meier estimates of PFS by investigator assessment in patients with expression of HER2 mRNA below the
median. The hazard ratio for progression was 0.85 (95% CI 0.44, 1.67). (B) Kaplan-Meier estimates of PFS by investigator assessment in patients with
expression of HER2 mRNA equal to or greater than the median. The hazard ratio for progression was 0.39 (95% CI 0.18, 0.85). HER2, human epidermal
growth factor receptor 2; HR, hazard ratio; HT, trastuzumab plus docetaxel; mRNA, messenger RNA; NR, not reached; T-DM1, trastuzumab emtansine.
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additional patients) likely due to the relatively high
concordance rate between local and central HER2 test-
ing in this study. The retrospective and exploratory
analysis reported here was carried out to investigate
the relationship between the efficacy benefit of T-DM1
compared with HT and HER2 mRNA expression
levels in TDM4450g. The results suggest that while
T-DM1 provides clinical benefit in patients with
HER2-positive tumors by standard criteria, the mag-
nitude of efficacy of T-DM1 versus HT may be more
pronounced in patients with tumors that exhibit
HER2 mRNA expression above the median. This cor-
relation suggests that high HER2 mRNA expression
that results in higher expression of HER2 protein
could lead to greater receptor presence on the cell
surface that in turn may result in increased delivery
of the cytotoxic agent DM1.The results obtained from our analysis also highlight the
importance of using the best available test to establish
HER2 status. At present, patients are selected for HER2-
targeted treatment based on the results of HER2 testing of
their primary tumor, which is most commonly determined
using either IHC or FISH [15]. In both cases, the result of
HER2 testing is given as either positive or negative, and
patients with HER2-positive tumors are considered to be
eligible for treatment with an HER2-targeted agent. It is
therefore imperative that individuals conducting HER2
testing ensure that the results they obtain are as accurate
as possible. Our results suggest that qRT-PCR may be able
to provide a more quantitative assessment of HER2 ex-
pression that could be used in addition to the standard
tests for determining tumor HER2 status.
The findings from our exploratory analysis are hypothesis-
generating only and should be interpreted with caution be-
cause of the limitations in the design of study TDM4450g.
HT T-DM1 
Biomarker subgroup 
Total 
No. No. 
No.  
events 
Median  
(months) No. 
No. 
events 
Median 
(months) 
Hazard ratio 
(95% CI) 
T-DM1 
better 
HT 
better 
HER2 mRNA
<Median 58 32 23 9.8 26 14 10.6 0.85 (0.44 to 1.67) 
Median 58 29 18 8.8 29 11 NR 0.39 (0.18 to 0.85) 
HER2 mRNA quartile
Min–25th 29 12 10 6.1 17 10 10.6 0.68 (0.28 to 1.65) 
25th–50th 29 20 13 10.6  9  4 11.0 1.47 (0.45 to 4.77) 
50th–75th 29 11  9 8.4 18  7 NR 0.33 (0.12 to 0.92) 
75th–Max 29 18  9 10.4 11  4 NR 0.36 (0.09 to 1.39) 
Hazard ratio 0.1 0.5 1 2 5
Figure 2 Progression-free survival during first-line treatment by investigator assessment by biomarker subgroups. The hazard ratios and
95% CIs for PFS are shown by HER2 mRNA subgroup (that is, below the median versus equal to or greater than the median, and by quartile).
HER2, human epidermal growth factor receptor 2; HT, trastuzumab plus docetaxel; max, maximum; min, minimum; NR, not reached; T-DM1,
trastuzumab emtansine.
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the subgroups (fewer than 33 patients for all subgroups).
These subgroup analyses are not statistically powered to de-
tect a difference, their main purpose being to evaluate
consistency of the effect across subgroups and to generate
hypotheses to be tested in phase III studies. The study mayHER2 mRNA quartile
HT T-DM1
Biomarker subgroup 
Total 
No. No. 
Response 
(%) No. 
Response 
(%) 
HER2 mRNA
<Median 57 31 58.1 26 53.8 0
Median 58 29 65.5 29 72.4 1
Min–25th 28 12 50.0 16 50.0 1
25th–50th 29 19 63.2 10 60.0 0
50th–75th 29 12 58.3 17 64.7 1
75th–Max 29 17 70.6 12 83.3  4
Odds rat
Figure 3 Objective response during first-line treatment by investigato
CIs for objective response rates are shown by HER2 mRNA subgroup (that
by quartile). HER2, human epidermal growth factor receptor 2; HT, trastuzum
emtansine. *Odds ratio is defined as complete or partial response determined
the response evaluation criteria in solid tumors [13]. Odds ratio relative to t
was defined as the ratio of the odds of having a response in the T-DM1also have been subject to bias, being open-label in design
with investigator-assessed end points. Nevertheless, a poten-
tial association between HER2 mRNA expression and re-
sponse to therapy has been reported in two phase II studies
of single-agent T-DM1 [11,12]. In both of these studies, the
median PFS was longer and the ORRs were greater inOdds ratio*
(95% CI) 
HT
better 
T-DM1
better 
.84 (0.30 to 2.41)
.58 (0.50 to 4.98)
.00 (0.22 to 4.47)
.87 (0.18 to 4.21)
.31 (0.29 to 5.98)
.17 (0.42 to 41.76)
io 0.1 0.5 1 2 5 
r assessment by biomarker subgroups. The odds ratios and 95%
is, below the median versus equal to or greater than the median, and
ab plus docetaxel; max, maximum; min, minimum; T-DM1, trastuzumab
on two consecutive tumor assessments at least 4 weeks apart based on
rastuzumab plus docetaxel was estimated by logistic regression. It
arm and the odds in the trastuzumab plus docetaxel arm.
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http://breast-cancer-research.com/content/16/3/R50patients with HER2 mRNA expression at or greater than
the median compared with those reported in patients with
HER2 mRNA expression below the median. It is important
to bear in mind, however, that both of those studies were
also relatively small (approximately 25 to 35 patients per
HER2 mRNA group) and had single-arm designs. Finally, in
the majority of patients, HER2 mRNA was determined on
tissue from the primary tumor. HER2 expression may have
changed in the metastatic lesions. Such changes in HER2
expression have been documented [16,17]. However, these
changes in HER2 expression appear to occur in a small
number of patients (10% to 15%) [16,17]. We were unable
to assess the potential influence of changes in HER2 expres-
sion in our study because of the small number of patients
with tissue samples from metastatic sites.
The provocative data obtained in our study require valid-
ation in phase III trials. Preliminary results from EMILIA
(TDM4370g/BO21977) presented at the American Associ-
ation for Cancer Research suggest that the magnitude of
the OS benefit with T-DM1 versus lapatinib plus capecita-
bine may be correlated with HER2 mRNA level [18]. Fur-
ther analyses of HER2 mRNA expression in EMILIA, as
well as in the ongoing phase III MARIANNE (TDM4788g/
BO22589) and TH3RESA (TDM4997g/BO25734) trials,
will help to evaluate further the correlation between this
marker and clinical outcomes.
Conclusions
In this exploratory analysis, we analyzed the relationship
between tumor HER2 mRNA expression level and effi-
cacy in patients receiving HT or T-DM1 in a random-
ized phase II study. While patients treated with T-DM1
had a lower risk of disease progression relative to HT-
treated patients regardless of whether their tumors
expressed high (equal to or greater than the median) or
low (below the median) HER2 mRNA, the benefit was
more pronounced in patients with high HER2 mRNA. If
validated in phase III studies, these results suggest that
there may be a subgroup of patients with an exceptional
response to T-DM1 based on high HER2 mRNA expres-
sion levels.
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